Biomarkers associated with checkpoint inhibitors
- PMID: 27122549
- DOI: 10.1093/annonc/mdw181
Biomarkers associated with checkpoint inhibitors
Abstract
Checkpoint inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy across multiple types of cancer. However, only subgroups of patients respond to these therapies. Additionally, CPI can induce severe immune-related adverse events (irAE). Biomarkers that predict efficacy and toxicity may help define the patients who may benefit the most from these costly and potentially toxic therapies. In this study, we review the main biomarkers that have been associated with the efficacy (pharmacodynamics and clinical benefit) and the toxicity (irAE) of CPIs in patients.
Keywords: biomarkers; cancer; checkpoint inhibitors; immunotherapy.
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Comment in
-
Don't forget the host: a potential role for germinal polymorphisms as markers for checkpoint inhibitors.Ann Oncol. 2017 Feb 1;28(2):435-436. doi: 10.1093/annonc/mdw554. Ann Oncol. 2017. PMID: 28426100 No abstract available.
Similar articles
-
Predicting immunotherapy response through genomics.Curr Opin Genet Dev. 2021 Feb;66:1-9. doi: 10.1016/j.gde.2020.11.004. Epub 2020 Dec 8. Curr Opin Genet Dev. 2021. PMID: 33307238 Review.
-
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Oncologist. 2017 Jan;22(1):81-88. doi: 10.1634/theoncologist.2016-0189. Epub 2016 Aug 17. Oncologist. 2017. PMID: 27534574 Free PMC article. Review.
-
[Toxicity of immune checkpoints inhibitors].Rev Mal Respir. 2018 Dec;35(10):1028-1038. doi: 10.1016/j.rmr.2017.08.006. Epub 2018 Sep 10. Rev Mal Respir. 2018. PMID: 30213624 Review. French.
-
Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.Korean J Radiol. 2017 Jan-Feb;18(1):42-53. doi: 10.3348/kjr.2017.18.1.42. Epub 2017 Jan 5. Korean J Radiol. 2017. PMID: 28096717 Free PMC article. Review.
-
Recent advances in the clinical development of immune checkpoint blockade therapy.Cell Oncol (Dordr). 2019 Oct;42(5):609-626. doi: 10.1007/s13402-019-00456-w. Epub 2019 Jun 14. Cell Oncol (Dordr). 2019. PMID: 31201647 Review.
Cited by
-
Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians.Front Immunol. 2023 Mar 1;14:1088874. doi: 10.3389/fimmu.2023.1088874. eCollection 2023. Front Immunol. 2023. PMID: 36936913 Free PMC article. Review.
-
Regulation of the adaptation to ER stress by KLF4 facilitates melanoma cell metastasis via upregulating NUCB2 expression.J Exp Clin Cancer Res. 2018 Jul 28;37(1):176. doi: 10.1186/s13046-018-0842-z. J Exp Clin Cancer Res. 2018. PMID: 30055641 Free PMC article.
-
A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.J Immunother Cancer. 2018 Sep 18;6(1):90. doi: 10.1186/s40425-018-0408-9. J Immunother Cancer. 2018. PMID: 30227886 Free PMC article.
-
Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury.Front Immunol. 2021 Dec 1;12:774807. doi: 10.3389/fimmu.2021.774807. eCollection 2021. Front Immunol. 2021. PMID: 34925345 Free PMC article. Review.
-
Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.Curr Oncol. 2023 Aug 23;30(9):7802-7809. doi: 10.3390/curroncol30090566. Curr Oncol. 2023. PMID: 37754481 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
